JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hassan, S. B.
Right arrow Articles by Karlsson, M. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hassan, S. B.
Right arrow Articles by Karlsson, M. O.

Vol. 299, Issue 3, 1140-1147, December 2001

Model for Time Dependency of Cytotoxic Effect of CHS 828 in Vitro Suggests Two Different Mechanisms of Action

Saadia B. Hassan, Elin Jonsson, Rolf Larsson and Mats O. Karlsson

Division of Clinical Pharmacology, University Hospital (S.B.H., E.J., R.L.), and Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden (M.O.K.)

CHS 828 is a novel drug belonging to the cyanoguanidines. It has shown promising anticancer activity in many preclinical systems and is currently in early clinical trials. Our aim in this study was to assess the growth inhibitory effect of CHS 828 in comparison with paclitaxel, etoposide, and topotecan as a function of concentration and time. U937 GTB, RPMI 8226/S, MDA 231, primary cells from chronic lymphocytic leukemia, and normal mononuclear cells were exposed to CHS 828 and U937 GTB cells were exposed to paclitaxel, etoposide, and topotecan in 18 concentrations for times ranging from 1 to 72 h. Cell survival was measured after 72-h incubation by using the fluorometric microculture cytotoxicity assay. Nonlinear mixed effect modeling was used to model the concentration-effect curves with a modified Hill equation. Patterns of change of drug potency (IC50), slope of the concentration-effect curves, and plateau with time were studied. The log IC50 for CHS 828 decreased with log time in a sigmoid manner for all cell types tested. Although very steep at short and long incubation, the concentration-effect curves became shallow at intermediate times. The log IC50 for etoposide and topotecan was decreased with log time in a sigmoid manner. The log IC50 for paclitaxel decreased linearly with log time. The information obtained from modeling the cytotoxic effect of CHS 828 and changes of IC50 and slope parameters with exposure time suggests a heterogeneous cell response to CHS 828. This could indicate two distinct mechanisms of induction of cell death.


0022-3565/01/2993-1140$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
JNMHome page
M. Bergstrom, A. Monazzam, P. Razifar, S. Ide, R. Josephsson, and B. Langstrom
Modeling Spheroid Growth, PET Tracer Uptake, and Treatment Effects of the Hsp90 Inhibitor NVP-AUY922
J. Nucl. Med., July 1, 2008; 49(7): 1204 - 1210.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. N. Gardner and M. Fernandes
New tools for cancer chemotherapy: computational assistance for tailoring treatments
Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.-M. Kissmeyer, K. Krasilnikoff, J. Bergh, M. O. Karlsson, A. Lonnebo, and J. Ahlgren
A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy
Clin. Cancer Res., September 1, 2002; 8(9): 2843 - 2850.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.